NCT07158606View on ClinicalTrials.gov

Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

August 31, 2032

Conditions
Hemophilia A With Inhibitor
Interventions
DRUG

efanesoctacog alpha

Efanesoctacog alpha will be administered at a dose of 50 IU/kg two times weekly during the ITI Treatment Period. The site investigator will determine the dose of efanesoctacog alpha once the subjects reaches the Follow Up Period.

DRUG

Emicizumab

Emicizumab will be prescribed as standard of care bleed prevention.

Trial Locations (1)

53226

Versiti Wisconsin, Milwaukee

All Listed Sponsors
lead

Versiti

OTHER